55 results
8-K
EX-99.1
REPL
Replimune Group Inc
8 Feb 24
Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update
8:05am
in solid organ transplant recipients with skin cancers at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting in November 2023. The data … , multicenter Phase 1 study of RP2 as a single agent and in combination with nivolumab at the 20th Annual International Society for Melanoma Research
8-K
EX-99.1
REPL
Replimune Group Inc
5 Dec 23
Other Events
7:19am
melanoma during a plenary session at the 20th International Congress of the Society for Melanoma Research in November. Based on the data
8-K
EX-99.1
REPL
Replimune Group Inc
7 Nov 23
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
8:15am
data from the ARTACUS clinical trial of RP1 monotherapy in solid organ transplant recipients with skin cancers at the Society for Immunotherapy … International Society for Melanoma Research Congress on November 8, 2023.
RP2 and RP3 Phase 2 program
RP2 and RP3 in combination with atezolizumab
S-3ASR
hrux kgvbzh0rwm
3 Aug 23
Automatic shelf registration
8:45am
8-K
EX-99.1
7gklvlg ityt7686fz
3 Aug 23
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
8:09am
8-K
EX-99.1
omsoknwlgal t3
3 Feb 22
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
8:16am
8-K
EX-99.1
lh5ybh2mikx2o49lnt
4 Nov 21
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
8:13am